CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Where Do We Stand with Immunotherapy for Advanced Pancreatic Ductal Adenocarcinoma: A Synopsis of Clinical Outcomes.
Where Do We Stand with Immunotherapy for Advanced Pancreatic Ductal Adenocarcinoma: A Synopsis of Clinical Outcomes.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
胰腺癌是全球男女两性癌症相关死亡的第七大原因，预后极差，生存率低，仍是全球重大疾病负担。从组织学看，胰腺导管腺癌（PDAC）占所有胰腺癌的80%；多数患者确诊时已处于晚期，无法接受根治性手术。传统化疗的5年总生存率不足8%，促使科学家和临床医生寻找更有效的治疗策略。癌症免疫学领域的近期发现推动免疫治疗用于癌症治疗。免疫检查点抑制剂、过继细胞疗法和癌症疫苗已改变部分恶性肿瘤的治疗指南，但其在PDAC中的疗效仍有待明确。本文综述晚期或转移性PDAC患者免疫治疗临床结局的现有数据。
Pancreatic cancer is the seventh leading cause of cancer-related mortality in both sexes across the globe. It is associated with extremely poor prognosis and remains a critical burden worldwide due to its low survival rates. Histologically, pancreatic ductal adenocarcinoma (PDAC) accounts for 80% of all pancreatic cancers; the majority of which are diagnosed at advanced stages, which makes them ineligible for curative surgery. Conventional chemotherapy provides a five-year overall survival rate of less than 8% forcing scientists and clinicians to search for better treatment strategies.
Recent discoveries in cancer immunology have resulted in the incorporation of immunotherapeutic strategies for cancer treatment. Particularly, immune-checkpoint inhibitors, adoptive cell therapies and cancer vaccines have already shifted guidelines for some malignancies, although their efficacy in PDAC has yet to be elucidated. In this review, we summarize the existing clinical data on immunotherapy clinical outcomes in patients with advanced or metastatic PDAC.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
